Palisade Bio, Inc.
PALI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $250 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $250 | $0 | $0 |
| % Margin | – | 100% | – | – |
| R&D Expenses | $9,063 | $6,893 | $6,547 | $2,430 |
| G&A Expenses | $5,796 | $6,202 | $8,764 | $9,307 |
| SG&A Expenses | $5,796 | $6,202 | $8,764 | $9,307 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $225 | $410 | $30,117 |
| Operating Expenses | $14,859 | $13,320 | $15,721 | $41,854 |
| Operating Income | -$14,859 | -$13,070 | -$15,721 | -$41,854 |
| % Margin | – | -5,228% | – | – |
| Other Income/Exp. Net | $421 | $770 | $1,461 | $15,238 |
| Pre-Tax Income | -$14,438 | -$12,300 | -$14,260 | -$26,616 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,438 | -$12,300 | -$14,260 | -$26,616 |
| % Margin | – | -4,920% | – | – |
| EPS | -10.19 | -27.01 | -16.53 | -2,144.25 |
| % Growth | 62.3% | -63.4% | 99.2% | – |
| EPS Diluted | -10.19 | -27.01 | -16.53 | -2,546.1 |
| Weighted Avg Shares Out | 1,416 | 456 | 880 | 12 |
| Weighted Avg Shares Out Dil | 1,416 | 456 | 880 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $13 | $0 |
| Interest Expense | $12 | $15 | $13 | $2,398 |
| Depreciation & Amortization | $3 | $4 | $3 | $2 |
| EBITDA | -$14,423 | -$12,281 | -$14,244 | -$24,216 |
| % Margin | – | -4,912.4% | – | – |